AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma

ANAPTYSBIO, INC

CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.
Jemperli royalties tiered: 8% up to $1B sales, 12% $1-1.5B, 20% $1.5-2.5B, 25% above $2.5B; GSK peak sales guide >£2B.
Sagard monetization capped at $600M; expected paydown mid-2027 to Q2 2028.
Biopharma Co pipeline: rosnilimab (Phase 2b RA, Phase 2 UC top-line Nov/Dec 2025), ANB033 (celiac Ph1b), ANB101 (Ph1a).
Separation targeted by year-end 2026; taxable but minimizing taxes; subject to board and SEC approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.